We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AVEO Pharmaceuticals (AVEO) Q1 Earnings: What's in Store?
Read MoreHide Full Article
AVEO Pharmaceuticals, Inc. is expected to report first-quarter 2018 results on May 3.
In the last reported quarter, AVEO delivered a negative surprise of 300%.
The company has slightly underperformed the industry so far this year. The stock fell 9.7% compared with a decline of 9.1% for the industry.
Let’s see how things are shaping up for this quarter.
Factors at Play
Following its launch last year in Germany, Fotivda, a first-line treatment for patients with advanced renal cell carcinoma (“RCC”) became the first commercial product in AVEO’s portfolio. The company is entitled to receive double-digit royalty payments from its partner, EUSA Pharma on net sales of the drug in Europe. We expect it to boost the company’s first-quarter revenues. The Zacks Consensus Estimate stands at $1.65 million.
In February 2018, Fotivda was granted positive recommendation for approval in the United Kingdom for the treatment of patients with advanced RCC. The recommendation triggered a payment of $2 million from EUSA Pharma.
Fotivda is currently being evaluated in a couple of studies for the third-line treatment of RCC and advanced RCC. In December 2017, the company announced completion of enrollment in phase II portion of phase I/II TiNivo study, evaluating Fotivda in combination with Bristol-Myers’ (BMY - Free Report) Opdivo in RCC. We expect the company to provide an update on these studies on its first-quarter earnings call.
Apart from Fotivda, AVEO is also developing ficlatuzumab in combination with Lilly’s Erbitux in a phase II study for treating metastatic head and neck squamous cell carcinoma. Another phase Ib study is evaluating the candidate in combination with Nab-paclitaxel and Gemcitabine in treatment-naive pancreatic cancer. These studies were initiated during the fourth quarter 2017.
Investor focus will likely remain on updates related to Fotivda’s launch and progress of ficlatuzumab.
Surprise History
AVEO’s performance over the last four quarters has been mixed. The company surpassed expectations thrice and missed once with an average negative surprise of 53.08%.
Earnings Whispers
Our proven model does not conclusively show that AVEO is likely to beat estimates in the soon-to-be reported quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Zacks ESP: Earnings ESP is 0.00% the Most Accurate estimate and the Zacks Consensus Estimate, are both pegged at a loss of 7 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: AVEO has a Zacks Rank #5 (Strong Sell).
Note that we caution against stocks with a Zacks Rank #4 (Sell) or 5 going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Here are some biotech stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat in their upcoming release.
Vanda Pharmaceuticals Inc. (VNDA - Free Report) has an Earnings ESP of +25% and a Zacks Rank #2. The company is scheduled to release first-quarter results on May 2.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
AVEO Pharmaceuticals (AVEO) Q1 Earnings: What's in Store?
AVEO Pharmaceuticals, Inc. is expected to report first-quarter 2018 results on May 3.
In the last reported quarter, AVEO delivered a negative surprise of 300%.
The company has slightly underperformed the industry so far this year. The stock fell 9.7% compared with a decline of 9.1% for the industry.
Let’s see how things are shaping up for this quarter.
Factors at Play
Following its launch last year in Germany, Fotivda, a first-line treatment for patients with advanced renal cell carcinoma (“RCC”) became the first commercial product in AVEO’s portfolio. The company is entitled to receive double-digit royalty payments from its partner, EUSA Pharma on net sales of the drug in Europe. We expect it to boost the company’s first-quarter revenues. The Zacks Consensus Estimate stands at $1.65 million.
In February 2018, Fotivda was granted positive recommendation for approval in the United Kingdom for the treatment of patients with advanced RCC. The recommendation triggered a payment of $2 million from EUSA Pharma.
Fotivda is currently being evaluated in a couple of studies for the third-line treatment of RCC and advanced RCC. In December 2017, the company announced completion of enrollment in phase II portion of phase I/II TiNivo study, evaluating Fotivda in combination with Bristol-Myers’ (BMY - Free Report) Opdivo in RCC. We expect the company to provide an update on these studies on its first-quarter earnings call.
Apart from Fotivda, AVEO is also developing ficlatuzumab in combination with Lilly’s Erbitux in a phase II study for treating metastatic head and neck squamous cell carcinoma. Another phase Ib study is evaluating the candidate in combination with Nab-paclitaxel and Gemcitabine in treatment-naive pancreatic cancer. These studies were initiated during the fourth quarter 2017.
Investor focus will likely remain on updates related to Fotivda’s launch and progress of ficlatuzumab.
Surprise History
AVEO’s performance over the last four quarters has been mixed. The company surpassed expectations thrice and missed once with an average negative surprise of 53.08%.
Earnings Whispers
Our proven model does not conclusively show that AVEO is likely to beat estimates in the soon-to-be reported quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Zacks ESP: Earnings ESP is 0.00% the Most Accurate estimate and the Zacks Consensus Estimate, are both pegged at a loss of 7 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: AVEO has a Zacks Rank #5 (Strong Sell).
Note that we caution against stocks with a Zacks Rank #4 (Sell) or 5 going into an earnings announcement, especially when the company is seeing negative estimate revisions.
AVEO Pharmaceuticals, Inc. Price and EPS Surprise
AVEO Pharmaceuticals, Inc. Price and EPS Surprise | AVEO Pharmaceuticals, Inc. Quote
Stocks That Warrant a Look
Here are some biotech stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat in their upcoming release.
Emergent Biosolutions Inc. (EBS - Free Report) has an Earnings ESP of +61.8% and a Zacks Rank #2. The company is scheduled to release first-quarter results on May 3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Vanda Pharmaceuticals Inc. (VNDA - Free Report) has an Earnings ESP of +25% and a Zacks Rank #2. The company is scheduled to release first-quarter results on May 2.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>